Literature DB >> 12002761

Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria.

John-Hendrik Jordan1, Gerit-Holger Schernthaner, Robert Fritsche-Polanz, Wolfgang R Sperr, Manuela Födinger, Andreas Chott, Klaus Geissler, Klaus Lechner, Hans-Peter Horny, Peter Valent.   

Abstract

Although systemic mastocytosis (SM) is a well-defined hematologic neoplasm, it is sometimes difficult to discriminate between SM and a reactive mast cell (MC) hyperplasia. We describe a patient with aplastic anemia who was treated with recombinant stem cell factor (SCF). In response to SCF, the patient showed transient hematologic improvement and developed a marked increase in MC as well as a transient increase in serum tryptase. Histologic and immunohistochemical examination revealed a huge increase in MC in the bone marrow with focal infiltrates similar to SM. However, most of the SM-criteria were not met: First, MC showed normal cytomorphological characteristics without significant atypias (no cytoplasmic extensions, no oval nuclei, no hypogranulated cytoplasm). Furthermore, bone marrow MC were CD2- and CD25-negative and did not exhibit the C-KIT 2468 A-->T mutation (Asp-816-Val). After discontinuation of SCF the MC hyperplasia resolved confirming its reactive nature. Based on our case and similar cases mimicking mastocytosis, it seems of importance to apply recently established SM criteria in order to discriminate between reactive MC hyperplasia and true mastocytosis with certainty.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12002761     DOI: 10.1080/10428190290012065

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  The role of mast cells in bone marrow diseases.

Authors:  O Ozdemir; S Savaşan
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

2.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

3.  The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.

Authors:  H-P Horny; K Sotlar; F Stellmacher; M Krokowski; H Agis; L B Schwartz; P Valent
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

4.  [Mastocytosis and eosinophilic leukemia: diagnostics and classification].

Authors:  K Sotlar; P Valent; H-P Horny
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

5.  Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.

Authors:  Hartmut Merz; Christian Kaehler; Kai P Hoefig; Biggi Branke; Wolfgang Uckert; Roger Nadrowitz; Sabine Cerny-Reiterer; Harald Herrmann; Alfred C Feller; Peter Valent
Journal:  Oncotarget       Date:  2010-06

6.  Demonstration and implications of IL-3 upregulation of CD25 expression on human mast cells.

Authors:  Yuzhi Yin; Yun Bai; Ana Olivera; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2021-09-08       Impact factor: 14.290

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.